Amtagvi

ASCO

Pharma

ASCO: BMS' triplet, Iovance's Amtagvi-Keytruda target melanoma

In small first-line melanoma trials, BMS' triplet delivered a 58.7% overall response rate (ORR), while Iovance's combo posted an ORR of 65.2%.

Angus Liu May 23, 2024 5:00pm

Amtagvi

FDA approves first T-cell therapy for a solid tumor

Feb 17, 2024 12:15pm